This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Canadian Agency for Drugs and Technologies in Health (CADTH). Aripiprazole for pregnant women: safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Respose - Summary of Abstracts. 2014
One non-randomized study was identified regarding the safety and harms of aripiprazole in pregnant women.
Subject indexing assigned by CRD
Antipsychotic Agents; Congenital Abnormalitiesnic and Fetal Development; Fetus; Maternal Exposure; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Teratogenss
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: email@example.com
Date abstract record published